Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 5/20 | 0.63 |
| ▸ | CA1 | P00915 | 5/20 | 0.63 |
| ▸ | CA2 | P00918 | 5/20 | 0.63 |
| ▸ | CA9 | Q16790 | 5/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 8/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19746137 | 0.90 | TDP1 (0.70) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL20078355 | 0.89 | TDP1 (0.56) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL134329 | 0.89 | TDP1 (0.85) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL343629 | 0.89 | TDP1 (0.85) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL343419 | 0.89 | TDP1 (0.85) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL3025184 | 0.89 | TDP1 (0.85) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL137629 | 0.89 | TDP1 (0.85) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL5162656 | 0.89 | TDP1 (0.85) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL136815 | 0.89 | TDP1 (0.85) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL140853 | 0.89 | TDP1 (0.85) | TDP1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087337-A1 | COMPOUNDS, COMPOSITIONS AND METHODS RELATED TO ANTIMICROBIAL APPLICATIONS | VYOME THERAPEUTICS LIMITED (IN) | 2021-03-25 | — | — | US | disclosed |
| EP-3507325-A2 | COMPOUNDS, COMPOSITONS AND METHODS RELATED TO ANTIMICROBIAL APPLICATIONS | Vyome Therapeutics Limited (IN) | 2019-07-10 | — | — | EP | disclosed |
| WO-2018042367-A2 | COMPOUNDS, COMPOSITONS AND METHODS RELATED TO ANTIMICROBIAL APPLICATIONS | VYOME BIOSCIENCES PVT. LTD. (IN) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087337-A1 | COMPOUNDS, COMPOSITIONS AND METHODS RELATED TO ANTIMICROBIAL APPLICATIONS | CUTA, GMPS, MMP8 | TDP1 467/4885CA12 4130/4885CA1 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.